Status:
COMPLETED
Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
Multiple Sclerosis (MS) is a chronic autoimmune neurodegenerative disease of the central nervous system (CNS). The symptoms of MS are wide-ranging, but patients perceive loss of physical function (gai...
Eligibility Criteria
Inclusion
- Clinical definite Multiple Sclerosis diagnosis according to the McDonald criteria
- About to commence alemtuzumab (Lemtrada) treatment
- Expanded Disability Status Scale (EDSS) ≤ 5.5
- Signed informed consent
Exclusion
- Co-morbidities that prevent participation in the project (dementia, serious cognitive disorders etc.)
Key Trial Info
Start Date :
March 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03806387
Start Date
March 1 2017
End Date
June 30 2021
Last Update
September 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University, Health, Section for Sport Science
Aarhus, Jutland, Denmark, 8000